Review of Peregrine's Phase I Cotara(R) Clinical Data for Colorectal Cancer to Be Presented at Cancer Therapy Meeting

Peregrine Announces the Appointment of Prominent Scientist to Its Scientific Advisory Board

Peregrine Pharmaceuticals Announces Successful Completion of its Antibody Humanization Project with AERES Biomedical

Avid Bioservices Expands Manufacturing Capacity

Peregrine Pharmaceuticals to Present at UBS Global Life Sciences Conference

Peregrine Pharmaceuticals, Inc. Submits IND for Its Novel Anti-Cancer Agent Tarvacin(TM)

Peregrine Pharmaceuticals Extends its Platform of Novel Anti-Cancer Technologies

Peregrine Pharmaceuticals Announces Patient Enrollment Completion for Cotara(TM) Phase I Study for Colorectal Cancer

Peregrine Pharmaceuticals Licenses Additional Intellectual Property for Its Anti-Phospholipid Therapy Platform Technology

Peregrine Pharmaceuticals Announces Patent Grants for Vascular Targeting Agents